2
Oct 27 (Reuters) – Cipla, India's third-largest drugmaker by revenue, missed second-quarter profit estimates on Tuesday, as muted sales of generic Revlimid and stiff competition weighed on its US
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
